ReadTube
Back to Thomas Fordham Brewer MD MPH

Is High Cholesterol Clogging your Arteries: NEW Evidence (ft. Dave Feldman & Nick Norwitz)

Thomas Fordham Brewer MD MPHMarch 5, 20261h 35m
Topics29
Patient Frustration with High LDL on Low-Carb Diet0:01Widespread Issue and Chronic Disease Context1:01Introducing Guests and Study Context2:02Clarification on Paper Retraction3:30Background on Dave Feldman4:31Nick Norwitz's Background and Retraction Context5:30Core Logic on LDL and Plaque9:00Initial Study Findings10:04Chronology of Analyses11:30Efforts with Cleerly15:32Blinding Issues and Independent Analyses17:00Reasons for Excitement on Retraction20:30High-Level Clarifications21:31Steel Manning and Ongoing Efforts22:30Nick Norwitz Detailed Background25:03Broader Perspective on Medicine26:31Nick's Challenge to Critics and Departure29:42Implications for Laypeople on Low-Carb Diets with High LDL32:01Honeypot Analogy and Need for Good-Faith Critique42:03Lifestyle Interventions Outperform Medications59:02Questions on LDL and Small Dense LDL1:01:00Clinical Practice and Clearly Usage1:04:00Issues with Clearly Analysis1:12:01Plaque Regression Statistics1:21:00Cholesterol Code Documentary1:24:00Handling Data Issues and Retraction Debates1:29:01Gratitude to HeartFlow Partnership1:31:00Wrapping Up and Rain Checks1:32:02Closing Remarks1:34:03
In a Nutshell

A study on lean mass hyperresponders (metabolically healthy low-carb dieters with LDL 180-591 mg/dL) found no association between high LDL/ApoB and plaque progression, with low overall progression and some regression confirmed by HeartFlow and Qangio analyses, but flawed unblinded Cleerly data prompted voluntary paper retraction after failed reanalysis requests. Critics like Thomas Dayspring dismiss it despite consistent findings across blinded datasets showing baseline plaque—not LDL—predicts progression. Laypeople on keto/carnivore diets with high LDL but good metabolic markers should prioritize full risk assessment over statin monotherapy, as lifestyle improvements outperform drugs and challenge LDL-centric dogma.

AI-Generated Notes

These notes were generated by AI and may contain inaccuracies.

A patient on a low-carb diet reported LDL close to 200 to their doctor, who called it lethal and blamed the diet. The patient is metabolically healthy, exercises, lost weight, and reversed metabolic disease. Hundreds of similar patients are frustrated with doctors testing only LDL and prescribing statins without considering metabolic markers.

Doctors often test only LDL, prescribe statins, and move on. Patients feel they know more than their doctors. 80% of disease, death, and disability stems from chronic disease, mostly related to artery health with age.

Guests Dave Feldman and Nick Norwitz published data challenged by lipidologists like Thomas Dayspring, who claim it proves nothing. As a physician with personal experience and hundreds of patients, the host questions if LDL is the major cause of artery issues and if statin prescriptions based solely on LDL tests are appropriate.

The paper has not been posted as retracted; authors requested withdrawal in December, expecting confirmation as retraction in mid-January due to the Cleerly analysis. This is discussed on social media.

Dave Feldman is an early retired tech professional, skilled scientist, and high-level poker player.

Sign in to read the full notes

Get access to AI-generated notes, topic timestamps, and more.